Phase II Study of Azacitidine (Vidaza®, Aza) and Donor Lymphocyte Infusions (DLI) As First Salvage Therapy in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (allo-SCT): Final Results From the AZARELA-Trial (NCT-00795548)

被引：5

作者：

Schroeder, Thomas ^{[1
]}

Czibere, Akos ^{[2
]}

Kroeger, Nicolaus ^{[3
]}

Platzbecker, Uwe ^{[4
]}

Bug, Gesine ^{[5
]}

Uharek, Lutz ^{[6
]}

Luft, Thomas ^{[7
]}

Wolschke, Christine ^{[8
]}

Bruns, Ingmar

Zohren, Fabian

Fenk, Roland

Haas, Rainer

Kobbe, Guido ^{[2
]}

机构：

[1] Univ Dusseldorf, Univ Hosp, D-40225 Dusseldorf, Germany

[2] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, D-40225 Dusseldorf, Germany

[3] Univ Med Ctr Hamburg Eppendorf, Clin Stem Cell Transplantat, Hamburg, Germany

[4] Univ Klinikum Carl Gustav Carus, Med Klin & Poliklin 1, Dresden, Germany

[5] Goethe Univ Frankfurt, Med Klin 2, Frankfurt, Germany

[6] Univ Hosp Berlin, Charite, Dept Hematol & Oncol, Berlin, Germany

[7] Univ Heidelberg, Heidelberg, Germany

[8] Univ Med Ctr Hamburg Eppendorf, Ctr Oncol, Bone Marrow Transplantat Unit, Hamburg, Germany

来源：

关键词：

D O I：

10.1182/blood.V118.21.656.656

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：300 / 300

页数：1